Cellumed Signs Technology Development Contract for Manufacturing Specific Enzymes for mRNA Vaccines
[Asia Economy Reporter Minji Lee] Cellumed announced on the 13th that it has signed a technology development outsourcing contract with the German company ARTES Biotechnology GmbH for the production of specific enzymes related to mRNA vaccines.
The company stated, "Cellumed intends to outsource the development of two types of mRNA vaccine production enzymes through ARTES Biotechnology GmbH," and added, "After completing the outsourced development, we plan to transfer the technology and outsource production (CMO) to Richter Helm Biologics, a partner company of ARTES."
Hot Picks Today
![[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"](https://cwcontent.asiae.co.kr/asiaresize/93/2026052014513970767_1779256299.png)
[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The advance payment that Cellumed must provide to the company is 1.31 billion KRW, with milestones totaling 5.02 billion KRW, making the total contract amount approximately 15.8% of its equity capital.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![[Breaking] Samsung Electronics Labor and Management Officially Sign Tentative Agreement](https://cwcontent.asiae.co.kr/asiaresize/307/2026052022492353201A.jpg)
